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Abstract
Background: Although tick-borne pathogens have been reported as an important cause of imported fever, the
incidence of Anaplasma phagocytophilum, the causative agent of human granulocytic anaplasmosis (HGA), in
travellers is unknown.
Methods: We conducted a prospective cohort study to investigate the aetiologies of fever in returning travellers
(November 2017—July 2019). Polymerase chain reaction for msp2 gene amplification and indirect immunofluores-
cence assay for A. phagocitophilum were performed in all returning travellers with undifferentiated non-malarial
fever.
Results: Among 141 travellers included, 8 patients were diagnosed with probable or confirmed HGA. The overall
incidence rate of HGA was 19.9 cases/1000 person—week of travel. The main destination of travel was Asia,
accounting for 62.5% patients with HGA. Co-infections were found in 37.5% of patients with HGA.
Conclusions: Diagnosis of HGA and empirical treatment with doxycycline should be considered in travellers with
fever.
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Introduction
Coronavirus disease 2019 (COVID-19) pandemic has brought
out the difficulties of facing the diagnosis and treatment of
emerging infections, especially those presenting with imported
fever.1 Febrile illness is estimated to occur in about 2–3% of
returning travellers and accounts for up to 25% of patients
seeking medical care in travel clinics.2 ,3 After ruling out common
diseases such as malaria or arboviral infections, a large number
of undifferentiated fever cases remain undiagnosed.4 Recently,
some studies performed in endemic areas showed that pathogens
transmitted by ticks or mites such as Orientia tsutsugamushi and
several species of Rickettsia spp. must be considered as causative
agents in non-malarial febrile illnesses.5
Anaplasma phagocytophilum is an obligate, intracellular
Gram-negative bacteria transmitted by hard ticks from the family
Ixodidae. It is the aetiological agent of Human Granulocytic
Anaplasmosis (HGA), usually presenting as an undifferenti-
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cytopenias.6 HGA can range from an asymptomatic self-
limiting infection to a multi-organ failure fatal disease, requiring
hospitalization in one-half of cases.6 ,7
HGA has mainly been described in America and Europe but,
like other rickettsial infections, it seems to be severely underre-
ported.6 Besides factors such as climate change, the increase of
international travels has been suggested as an important cause
of the emergence of tick-borne infections.7–9 Although HGA has
been occasionally reported in febrile travellers,10 incidence of
HGA among returning travellers is unknown.
Methods
We performed a prospective cohort study in patients presenting
with fever within 28 days after an international trip at the
Hospital Clinic of Barcelona (HCB), Spain, from November 2017
to July 2019. Inclusion criteria were temperature ≥37.5◦C or
feverish sensation accompanied by 2 of the 3 following symp-
toms: arthralgia, myalgia or chills. Patients younger than 18 years
old and those requiring admission in a high-level isolation unit
were excluded. In order to rule out malaria, a blood smear
was systematically performed in all febrile travellers or migrants
returning from malaria endemic areas. Patients presenting with
≥3 stools per day, prominent cough, expectoration or dyspnea,
urinary tract infection symptoms or signs consistent with skin
or soft tissue infections were considered as differentiated fevers
and were not eligible to participate. By contrary, febrile patients,
presenting with no clear source of infection in whom malaria was
ruled out, were defined as undifferentiated non-malarial fever
(UNMF) cases and were eligible to participate.
In addition to the microbiological tests performed routinely
(Table 1), blood samples at first visit and 28 days (range:
21–72) later were obtained in study participants. Polymerase
chain reaction (PCR) for msp2 gene amplification in acute-phase
whole blood or plasma samples and indirect immunofluores-
cence assay (IFA) for A. phagocitophylum (Focus Diagnostics,
Cypress, CA, USA) in paired sera were performed.6 ,11–13 In
patients diagnosed with HGA (either by IFA or PCR), PCRs
and serologies for spotted fever group Rickettsia spp., typhus
group Ricketssia spp., O. tsutsugamushi, Coxiella burnetii,
Bartonella quintana, Bartonella henselae and serology for
Borrelia burgdorferi were systematically performed in order to
rule out possible cross-reactions and/or co-infections. Based on
microbiological and clinical criteria, according to guidelines,6 ,12
and after expert discussion, patients were classified as confirmed
HGA, probable HGA or cases without active HGA (Table 1).
Cases with stable titres of A. phagocytophilum antibodies in
acute and convalescent sera and titres > 4-fold above the cut-off
value were classified as probable cases when they presented with
other confirmed infections. Possible co-infections were classified
according to the scheme proposed by Phommarone et al.14
Overall incidence of HGA was presented as an incidence rate
(IR) of confirmed and probable cases. Period at risk for HGA
was considered as the time from the beginning of the trip until
the onset of fever in participants diagnosed with HGA presenting
with fever during the trip and as the overall duration of travel
in the others. For the IR calculation, long trips (≥6 months),
expatriates and long term residents were excluded from the
analysis.
Categorical variables are presented in percentages and quanti-
tative variables are presented as median and interquartile ranges
(IQR). Fisher’s exact test was used to compare categorical vari-
ables between groups, while Mann–Whitney U test was used for
quantitative variables. The statistical analysis was carried out
using Stata 15 (StataCorp.2017).
The study was conducted following the principles of the
Declaration of Helsinki. The ethical committee of the HCB
approved the study (HCB/2017/0612). Informed written consent
was given by all participants.
Results
Incidence of HGA among febrile
returning travellers
During the study period, 141 patients with available paired sera
out of a total of 179 patients with UNMF were included in
the study. Of them, a total of 8 patients were diagnosed with
probable or confirmed HGA, showing an overall IR of HGA
of 19.9 cases/1000 person—week of travel (95%CI: 9.6–41.5).
Figure 1 illustrates the microbiological results of participants
with HGA.
Two participants fulfilled the criteria for confirmed HGA.
One had a seroconversion with no alternative diagnosis. The
other confirmed case was diagnosed both by seroconversion and
amplification of msp2 gene, with subsequent A. phagocitophilum
sequencing. Based on confirmed cases, minimum IR of HGA is
estimated to be 5.7 cases/1000 person—week of travel (95%CI:
1.4–22.6).
Six participants fulfilled the criteria for probable HGA. Two
of them presented seroconversion for A. phagocitophylum and
an alternative diagnosis. The other 4 participants presented
with high positive IFA titers (≥64) in acute and convalescent
sera or <4-fold elevation of IFA titers for A. phagocitophylum.
Then, IR of probable HGA was estimated to be 14.2 cases/1000
person with UNMF—week of travel (95%CI: 6.0–34.0). Data
on incidence of probable and confirmed HGA are summarized
in Table 1.
Among the 141 patients with UNMF included, positive IFA
for A. phagocytophilum was detected in an additional 9 partici-
pants (17 patients in total), showing a global seroprevalence of A.
phagocytophilum IgG antibodies of 12.1% (95%CI: 7.2–18.6).
Epidemiological and clinical characteristics
of travellers diagnosed with HGA
Table 2 describes the epidemiological and clinical features of the
8 travellers with HGA. The main destination of travel was Asia,
accounting for 5 cases (62.5%). Indeed, the two confirmed cases
of HGA came from Thailand and Malaysia. All of them visited
rural areas. Three (37.5%) patients presented a clear risk of tick
exposure: two of them had contact with animals and only one
referred a tick bite, but none of them presented with an eschar on
physical exam. The maximal incubation period (measured from
the last day of the trip) was 6 days. All patients presented fever
within the first 24 hours of symptoms’ onset. Other common
symptoms were arthralgia, myalgia, malaise, headache and rash.
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Table 1. Incidence and definition criteria of confirmed and probable HGA
Confirmed HGA Probable HGAa
Case definition Compatible clinical presentation AND: (i) positive PCR
assay and A. phagocytophilum sequencing OR
(ii) seroconversion or ≥ 4-fold increase of IFA titers with
no alternative confirmed diagnosis.b
Compatible clinical presentation AND:
(i) seroconversion or ≥ 4-fold increase of IFA titers with
an alternative confirmed diagnosisa OR
(ii) high positive IFA titers (≥64) in acute and
convalescent sera or < 4-fold elevation of IFA titers
with no alternative diagnosis.b
IRc 5.7 cases/1000 person with UNMF—week of travel 14.2 cases/1000 person with UNMF—week of travel
95% CI 1.4–22.6 cases/1000 person with UNMF—week of travel 6.0–34.0 cases/1000 person with UNMF—week of travel
CI: confidence interval. IFA: indirect immunofluorescence assay.
aDefinition criteria for confirmed and probable HGA adapted from international guidelines.6
bPCRs and serologies against dengue virus, chikungunya virus and Zika virus were routinely performed in all patients presenting with fever ≤ 14 days after the trip. PCRs and serologies
for spotted fever group Rickettsia spp., typhus group Ricketssia spp., O. tsutsugamushi, C. burnetii, B. quintana, B. henselae and serology for B. burgdorferi were systematically performed
in patients diagnosed with HGA. Tests looking for other infections such as leptospirosis or HIV were performed based on clinical suspicion and risk exposures.
cLong trips (≥6 months), expatriates and long-term residents excluded.
Figure 1. Flowchart of study participants with HGA.
IFA: indirect immunofluorescence assay. IgG: immunoglobulin G. α38 patients with no convalescent serum sample were excluded from the study
βWithout an alternative diagnosis μIn acute and convalescent sera. π Not fulfilling criteria of previous categories.
mild elevation of C-reactive protein (62.5%). The aforemen-
tioned clinical and demographic characteristics did not differ
between travellers with HGA and those without HGA (Table 2).
Although only 2 (25.0%) patients received an adequate
antibiotic treatment (doxycycline 100 mg bid for 7–14 days),
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Male sex, n/N (%) 1/2 (50.0) 3/6 (50.0) 4/8 (50.0) 71/133 (53.4) >0.999b
Age (years), Md (IQR) 40.5 (39–42)c 26 (26–53) 32.5 (26–47.5) 34 (28–43) 0.954d
Travel region, n/N (%) 0.938b
• Asia/Southeast Asiae 2/2 (100) 3/6 (50.0) 5/8 (62.5) 61/132 (46.2)
• Africaf 0/2 2/6 (33.3) 2/8 (25.0) 33/132 (25.0)
• Americag 0/2 1/6 (16.7) 1/8 (12.5) 29/132 (22.0)
• Europe 0/2 0/6 0/8 9/132 (6.8)
Duration of travel (days), Md (IQR) 16.5 (16–17) 15.5 (13–16) 16 (14–16.5) 17 (12–26) 0.688d
Risk factors, n/N (%)
• Rural areas 2/2 (100) 6/6 (100) 8/8 (100) 118/133 (88.7) 0.600b
• Animal contact 1/2 (50.0) 1/6 (16.7) 2/8 (25.0) 58/133 (43.6) 0.467b
• Tick bite 0/2 1/6 (16.7) 1/8 (12.5) 18/133 (13.5) >0.999b
Days of fever, Md (IQR) 3.5 (3–4)c 6 (2–6) 4 (2–6) 5 (3–7) 0.864d
Symptoms and signs, n/N (%)
• Fever 2/2 (100) 6/6 (100) 8/8 (100) 133/133 (100) -
• Malaise/fatigue 1/2 (50.0) 5/6 (83.3) 6/8 (75.0) 105/133 (78.9) 0.678b
• Headache 1/2 (50.0) 5/6 (83.3) 6/8 (75.0) 99/133 (74.4) >0.999b
• Arthralgia/myalgia 2/2 (100) 3/6 (50.0) 5/8 (62.5) 97/133 (72.9) 0.685b
• Rash 2/2 (100) 2/6 (33.3) 4/8 (50.0) 54/133 (40.6) 0.717b
• Eschar 0/2 0/6 0/9 11/133 (8.3) >0.999b





































• Elevated CRP 1/2 (50.0) 4/6 (66.7) 5/8 (62.5) 81/133 (60.9) >0.999b
• Elevated transaminases 1/2 (50.0) 2/6 (33.3) 3/8 (37.5) 68/133 (51.1) 0.493b
Hospital admission, n/N (%) 0/2 1/6 (16.7) 1/8 (12.5) 26/133 (19.5) >0.999b
Cure at 30 days, n/N (%) 2/2 (100) 6/6 (100) 8/8 (100) 101/133 (75.9) 0.198b
CPR: C-reactive protein. Md: Median. n: number of cases. N: total number of patients diagnosed with HGA.




eCountries visited in Asia included Thailand, Vietnam, Singapore, Malaysia, Indonesia and India.
fCountries visited in Africa included Madagascar and Angola.
gThe visited country in the America was Costa Rica.
Only one patient required hospital admission. One month after
inclusion, all patients but one were completely asymptomatic.
The only patient that was still symptomatic was diagnosed with
myelodysplastic syndrome; symptoms after 1 month were not
considered any more as related to A. phagocytophilum infection.
Co-infections
Three out of 8 HGA participants (37.5%) had confirmed, prob-
able or possible co-infections with Chikungunya, Dengue and C.
burnetii. Supplementary Table 1 shows detailed microbiological
information of HGA co-infections.
Discussion
The main finding of our study is an overall IR of HGA of
19.9 cases/1000 person with UNMF—week of travel, that means
that patients presenting with fever after an international travel
have an increased risk of HGA of almost 2% for every week
of travel. Although there is a scarcity on the available published
information about the incidence of HGA in travellers, our study
shows that the incidence of HGA among returning travellers
with fever is not negligible. In addition, the incidence of vector-
borne infections is expected to increase due to recent lockdowns
and breakdowns in control strategies in endemic areas due to
COVID-19 pandemic.15 As with some other neglected diseases,
the non-specific presentation of HGA, the low awareness of this
infection by physicians and the lack of access to diagnostic tools
in several centers can explain why HGA is currently underre-
ported.6–8 ,16 Moreover, since two patients had stable antibody
levels against A. phagocytophilum, we cannot completely rule
out that these patients acquired the infection in Spain before
travelling. This is not the case for the remaining patients. Time
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in all but one case, and time since the beginning of the trip to
the onset of fever was consistent with the usual median HGA
incubation period of 11 days (range 5–21).6 The only patient who
presented with fever 6 days after the last day of the trip denied
any exposure or risk factor for HGA since the arrival, making
very unlikely the acquisition of HGA in Spain.
Most cases of HGA have been previously reported in North
America and Europe.7 ,8 Nevertheless, in our study, A. phagocy-
tophilum infection was commonly found in travellers from Asia,
where A. phagocytophilum is increasingly been reported.7 ,17–21
Moreover, it has been communicated at least once in Africa22
and it has been found in ticks in South America.23 ,24 Despite the
relatively small sample size and the unicenter nature of the study,
data showed in this study add further evidence that distribution
of HGA is widespread.
In line with previous reports, possible co-infections were
detected in more than one third of cases in our cohort.19–21
Physicians must be aware of possible co-infections not only with
tick-borne microorganisms but also with mosquito-transmitted
arboviruses.
Although most cases presented a self-limited evolution, effec-
tive antibiotic treatment against intracellular bacteria such as
doxycycline should be considered in travellers with undifferenti-
ated fever presenting with severe disease, after excluding malaria
and, especially, if they had visited rural areas and/or presented
with cytopenias.5 ,20 ,21 ,24
In conclusion, HGA should be included in the differential
diagnosis of returning travellers with fever and no clear
source of infection. Antibiotic treatment such as doxycycline
should be considered in travellers with undifferentiated fever
presenting with severe disease, after discarding malaria and,
especially, if they had visited rural areas and/or presented with
cytopenias. Physicians must be aware of possible co-infections
with other tick-borne microorganisms and mosquito-transmitted
arboviruses.
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Supplementary data are available at JTM online.
Conflict of interests
The authors declare no conflict of interests.
Acknowledgements
This study was awarded with 2017–2018 International Society
of Travel Medicine (ISTM) Research Award.
References
1. Sanders JM, Monogue ML, Jodlowski TZ, Cutrell JB. Pharmacologic
treatments for coronavirus disease 2019 (COVID-19): a review.
JAMA 2020; 323:1824–36.
2. Hagmann SH, Han PV, Stauffer WM et al. Travel-associated disease
among US residents visiting US GeoSentinel clinics after return from
international travel. Fam Pract 2014; 31:678–87.
3. Buss I, Genton B, D’Acremont V. Aetiology of fever in returning
travellers and migrants: a systematic review and meta-analysis. J
Travel Med 2020; 27:taaa207. doi: 10.1093/jtm/taaa207 PMID:
33146395; PMCID: PMC7665639.
4. Bottieau E, Clerinx J, Schrooten W et al. Etiology and outcome of
fever after a stay in the tropics. Arch Intern Med 2006; 166:1642–8.
5. Mayxay M, Castonguay-Vanier J, Chansamouth V et al. Causes of
non-malarial fever in Laos: a prospective study. Lancet Glob Health
2013; 1:e46–54.
6. Brouqui P, Bacellar F, Baranton G et al. Guidelines for the diagnosis
of tick-borne bacterial diseases in Europe. Clin Microbiol Infect
2014; 10:1108–32.
7. Jin H, Wei F, Liu Q, Qian J. Epidemiology and control of
human granulocytic anaplasmosis: a systematic review. Vector Borne
Zoonotic Dis 2012; 12:269–74.
8. Blanco JR, Oteo JA. Human granulocytic ehrlichiosis in Europe. Clin
Microbiol Infect 2002; 8:763–72.
9. Jensenius M, Davis X, von Sonnenburg F et al. GeoSentinel surveil-
lance network. Multicenter GeoSentinel analysis of rickettsial dis-
eases in international travelers, 1996-2008. Emerg Infect Dis 2009;
15:1791–8.
10. Nitzan O, Blum A, Marva E et al. Case report: infectious diseases
in pilgrims visiting the holy land. Am J Trop Med Hyg 2017; 97:
611–4.
11. Courtney JW, Kostelnik LM, Zeidner NS, Massung RF. Multi-
plex real-time PCR for detection of anaplasma phagocytophilum
and Borrelia burgdorferi. J Clin Microbiol 2004; 42:3164–8. doi:
10.1128/JCM.42.7.3164-3168.2004.
12. Silaghi C, Santos AS, Gomes J et al. Guidelines for the direct detection
of Anaplasma spp. in diagnosis and epidemiological studies. Vector
Borne Zoonotic Dis 2017; 17:12–22.
13. Zeidner NS, Burkot TR, Massung R. Transmission of the agent
of human granulocytic Ehrlichiosis by Ixodes spinipalpis ticks:
evidence of an enzootic cycle of dual infection with Borre-
lia burgdorferi in northern Colorado. J Infect Dis 2000; 182:
616–9.
14. Phommasone K, Paris DH, Anantatat T et al. Concurrent infec-
tion with murine typhus and scrub typhus in southern Laos–the
mixed and the unmixed. PLoS Negl Trop Dis 2013; 7:e2163. doi:
10.1371/journal.pntd.0002163.
15. The potential impact of health service disruptions on the burden of
malaria: a modelling analysis for countries in sub-Saharan Africa.
Geneva: World Health Organization, 2020, Licence: CC BY-NC-SA
3.0 IGO.
16. Zammarchi L, Gobbi F, Angheben A et al. Schistosomiasis, strongy-
loidiasis and Chagas disease: the leading imported neglected tropical
diseases in Italy. J Travel Med 2020; 27:taz100. doi: 10.1093/jtm/-
taz100.
17. Blacksell SD, Kantipong P, Watthanaworawit W et al. Under-
recognized arthropod-borne and zoonotic pathogens in northern
and northwestern Thailand: serological evidence and opportunities
for awareness. Vector Borne Zoonotic Dis 2015; 15:285–90. doi:
10.1089/vbz.2015.1776.
18. Koh FX, Kho KL, Kisomi MG et al. Ehrlichia and Anaplasma
infections: serological evidence and tick surveillance in
peninsular Malaysia. J Med Entomol 2018; 55:269–76. doi:
10.1093/jme/tjx204.
19. Nooroong P, Trinachartvanit W, Baimai V, Ahantarig A. Phylo-
genetic studies of bacteria (Rickettsia, Coxiella, and Anaplasma)
in Amblyomma and Dermacentor ticks in Thailand and their co-
infection. Ticks Tick Borne Dis 2018; 9:963–71.
20. Heo DH, Hwang JH, Choi SH et al. Recent increase of human









 Bibliotheque user on 08 June 2021
6 Journal of Travel Medicine, 2021, Vol. 28, 4
Korean hemorrhagic fever with renal syndrome in Korea. J Korean
Med Sci 2019; 34:e87. doi: 10.3346/jkms.2019.34.e87.
21. Le-Viet N, Le VN, Chung H et al. Prospective case-control analysis
of the aetiologies of acute undifferentiated fever in Vietnam. Emerg
Microbes Infect 2019; 8:339–52.
22. Elhamiani Khatat S, Sahibi H, Hing M et al. Human exposure to
Anaplasma phagocytophilum in two cities of northwestern Morocco.
PLoS One 2016; 11:e0160880.
23. Pesquera C, Portillo A, Palomar AM, Oteo JA. Investigation of
tick-borne bacteria (Rickettsia spp., Anaplasma spp., Ehrlichia spp.
and Borrelia spp.) in ticks collected from Andean tapirs, cattle and
vegetation from a protected area in Ecuador. Parasit Vectors 2015;
8:46.
24. Licona-Enríquez J, Delgado-de la Mora J, Alvarez-Hernandez G.
Fatal case of co-infected of rickettsiosis and dengue virus in Mexico.









 Bibliotheque user on 08 June 2021
